Nkarta | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.29, beating the estimate of USD -0.3133.

EBIT: As of FY2025 Q3, the actual value is USD -31.14 M.

Segment Revenue

Nkarta, Inc. operates in one segment focused on the research and development of cell therapies for autoimmune diseases. The company has not generated revenue from product sales as of the report date.

Operational Metrics

Net Loss: For the three months ended September 30, 2025, the net loss was - $21.7 million, compared to - $28.3 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $76.7 million, compared to - $82.9 million for the same period in 2024.
Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $20.2 million, compared to $25.3 million for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $65.1 million, compared to $73.6 million for the same period in 2024.
General and Administrative Expenses: For the three months ended September 30, 2025, general and administrative expenses were $7.1 million, compared to $8.5 million for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $25.9 million, compared to $23.7 million for the same period in 2024.

Cash Flow

Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $67.1 million, compared to - $74.9 million for the same period in 2024.
Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided by investing activities was $99.2 million, compared to net cash used of - $125.0 million for the same period in 2024.
Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $77 thousand, compared to $225.9 million for the same period in 2024.

Unique Metrics

Accumulated Deficit: As of September 30, 2025, the company had an accumulated deficit of $620.9 million.

Future Outlook and Strategy

Core Business Focus: Nkarta, Inc. plans to continue its focus on the development of NKX019 for the treatment of autoimmune diseases, including lupus nephritis and systemic sclerosis. The company intends to raise additional capital through debt or equity financings to support its research and development activities.
Non-Core Business: The company has deprioritized further development of NKX070 and NK+T programs to focus resources on NKX019.
Priority: Nkarta, Inc. aims to streamline its operations and reduce costs, including a reduction in workforce announced in March 2025, to support its clinical data updates and strategic priorities.